Elitzur S, Arad-Cohen N, Barg A, et al. - In this nationwide multicentre study, researchers examined the features of mucormycosis in children with haematological malignancies. Study participants involved 39 children with mucormycosis: 25 of 1,136 children (incidence 2·2%) with acute leukaemias prospectively enlisted in a centralized clinical registry in 2004–2017, and an additional 14 children with haematological malignancies identified by retrospective search of the databases of seven paediatric haematology centres. In patients with acute leukaemias, 92% of mucormycosis cases occurred. Findings suggested a significant association of mucormycosis with high-risk acute lymphoblastic leukaemia and with increasing age. One-year cumulative mucormycosis-related mortality was 21 ± 8% and five-year overall survival was 70 ± 8% in patients receiving frontline therapy for their malignancy (n = 24). In this largest paediatric population-based study of mucormycosis, children receiving frontline therapy for their haematological malignancy are often salvageable.